Radical Prostatectomy News and Research

RSS

Radical prostatectomy is surgery to remove all of the prostate gland and some of the tissue around it, to treat prostate cancer.

First-degree family history of prostate cancer does not affect some treatment outcomes

In a first of its kind study, a first-degree family history of prostate cancer has no impact on the treatment outcomes of prostate cancer patients treated with brachytherapy (also called seed implants), and patients with this type of family history have clinical and pathologic characteristics similar to men with no family history at all, according to a January 1 study in the International Journal of Radiation Oncology*Biology*Physics , the official journal of the American Society for Radiation Oncology.

5 Jan 2009

Satisfaction and regret after radical prostatectomy procedures studied

Studies have shown that approximately 16% of patients with localised prostate cancer regret their treatment choice. European Urology, the official journal of the European Association of Urology, will be publishing an article by J.W. Moul et al. comparing differences in satisfaction and regret between patients who underwent open retropubic radical prostatectomy and robot-assisted laparoscopic radical prostatectomy.

26 Aug 2008

Brachytherapy may benefit obese prostate cancer patients

Brachytherapy, also called seed implants, may be a more beneficial treatment than surgery or external beam radiation therapy for overweight or obese prostate cancer patients, according to a study published in the August issue of the International Journal of Radiation Oncology-Biology-Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

19 Aug 2008

Prostatectomy improves outcome of some men with prostate cancer over watchful waiting

Men with early prostate cancer who undergo radical prostatectomy have a lower rate of death due to prostate cancer than men who are followed without treatment, known as watchful waiting, according to a randomized controlled trial published in the August 12 online issue of the Journal of the National Cancer Institute.

12 Aug 2008

Disparities in prostate cancer treatment suggest ways to improve care

Quality of care varies greatly for the treatment of men with early-stage prostate cancer by region of the country and category of health care facility, suggesting the potential for improved patient outcomes with more standard treatment protocols, according to a new study that was published in the Aug. 1 issue of the Journal of Clinical Oncology (2008: Vol. 26, Issue 22).

3 Aug 2008

Seven elevated biomarkers predict prostate cancer risk with 86.6 percent reliability

A simple blood test screening for a panel of biomarkers can accurately predict whether a patient who has had prostate cancer surgery will have a recurrence or spread of the disease.

26 Jun 2008

Seven biomarkers that may help pinpoint prostate cancer recurrence found

A simple blood test may help doctors better predict whether prostate cancer will recur or spread in patients who have undergone surgery for the disease, UT Southwestern Medical Center researchers have found.

24 Jun 2008

Seven biomarkers found that predict with 86 percent accuracy prostate cancer recurrence

A simple blood test may help doctors better predict whether prostate cancer will recur or spread in patients who have undergone surgery for the disease, researchers at UT Southwestern Medical Center have found.

17 Jun 2008

Radiation therapy prolongs life in men with recurrent prostate cancer

Men whose tumors recur after prostate cancer surgery are three times more likely to survive their disease long term if they undergo radiotherapy within two years of the recurrence. Surprisingly, survival benefits were best in men whose new tumors were growing fastest, according to results of a 'look-back' study of 635 men by Johns Hopkins Medical Institutions researchers reported June 18 in the Journal of the American Medical Association.

17 Jun 2008

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone - the hormone that fuels prostate-cancer growth - via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.

2 Jun 2008

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

1 Jun 2008

New study confirms that PROGENSA PCA3 can improve accuracy of prostate cancer diagnosis

New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.

20 Mar 2008

Live demonstration of robotic radical prostatectomy

One of the nation's top robotic surgeons will remove the cancerous prostate of a Southern Tier man during a live demonstration of robotic surgery on Wednesday, March 19.

19 Mar 2008

New blood biomarker accurately predicts spread of prostate cancer to regional lymph nodes

Researchers report finding a new blood biomarker that enables close to 98 percent accuracy in predicting the spread of prostate cancer to regional lymph nodes.

28 Feb 2008

IRIS International completes study of 85 post-prostatectomy patients using investigational NADiA PSA assay

IRIS International Inc. has announced that its Iris Molecular Diagnostics (IMD) group has successfully completed a retrospective study of stored leftover serum of 85 post-prostatectomy patients, men who had their prostate removed due to prostate cancer, using its investigational NADiA (Nucleic Acid Detection ImmunoAssay) PSA Assay.

27 Feb 2008

Effects of prostate removal

Men with prostate cancer who have their prostate removed cite sexual dysfunction as the most common side effect after surgery, but urinary dysfunction troubles these patients most, reports a University of Florida researcher. What's more, many aren't emotionally prepared to face these complications.

4 Feb 2008

Many prostate cancer patients receive wrong treatment

Prostate cancer patients often receive treatment that is contraindicated by pre-existing conditions, like urinary or bowel dysfunction, according to a new study.

26 Nov 2007

Doctors may be missing cancers in obese men due to misleading PSA scores

Doctors may be missing cancers in obese men because the telltale blood marker used to detect the disease can be falsely interpreted as low in this population, according to a new study led by Duke Prostate Center researchers.

21 Nov 2007

Radiation seed implant decreases risk of death over watchful waiting/active surveillance for prostate cancer

Prostate cancer patients cut their risk of dying of the disease in half when they receive radiation seed implants (brachytherapy) to treat their cancer, compared to those who don't receive active treatment (watchful waiting/active surveillance), within six months from being diagnosed with localized prostate cancer, according to a study presented October 31, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

1 Nov 2007

Radiation after surgery keeps high-risk prostate cancer at bay

An analysis of data involving more than 2,000 patients from 17 U.S. institutions demonstrates that men with high-risk prostate cancer who receive radiation therapy after a prostatectomy were less likely to have a recurrence of disease.

31 Oct 2007

Radical Prostatectomy News and Research

First-degree family history of prostate cancer does not affect some treatment outcomes

Satisfaction and regret after radical prostatectomy procedures studied

Brachytherapy may benefit obese prostate cancer patients

Prostatectomy improves outcome of some men with prostate cancer over watchful waiting

Disparities in prostate cancer treatment suggest ways to improve care

Seven elevated biomarkers predict prostate cancer risk with 86.6 percent reliability

Seven biomarkers that may help pinpoint prostate cancer recurrence found

Seven biomarkers found that predict with 86 percent accuracy prostate cancer recurrence

Radiation therapy prolongs life in men with recurrent prostate cancer

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

New study confirms that PROGENSA PCA3 can improve accuracy of prostate cancer diagnosis

Live demonstration of robotic radical prostatectomy

New blood biomarker accurately predicts spread of prostate cancer to regional lymph nodes

IRIS International completes study of 85 post-prostatectomy patients using investigational NADiA PSA assay

Effects of prostate removal

Many prostate cancer patients receive wrong treatment

Doctors may be missing cancers in obese men due to misleading PSA scores

Radiation seed implant decreases risk of death over watchful waiting/active surveillance for prostate cancer

Radiation after surgery keeps high-risk prostate cancer at bay

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News